Did Trump Approve Cannabis Interstate Commerce? Not Quite

Photo by Tom Jackson via Pexels.

Scroll through cannabis industry headlines this week and you'd think the interstate shipping floodgates just opened. "Cannabis Interstate Commerce Is Here," some are saying, with photos of trucks and warehouses to match. The reality, once you dig past the press release language, is a lot narrower and a lot more procedural than that framing suggests.

On April 23, 2026, Acting Attorney General Todd Blanche signed a DOJ order moving two specific categories of marijuana into Schedule III of the Controlled Substances Act. Not all marijuana. Two categories. The order traces directly back to an executive action Trump signed on December 18, 2025, titled "Increasing Medical Marijuana and Cannabidiol Research," which directed the DOJ to move on rescheduling quickly. What actually changed is a limited pathway for medical cannabis and research-grade product to cross state lines under federal oversight. Recreational marijuana, the stuff sold in adult-use dispensaries from California to Michigan, is still sitting at Schedule I, right alongside heroin, at least as far as federal law is concerned. Understanding exactly where the line falls matters a great deal if you're running a cannabis business, investing in one, or just trying to figure out what you can legally do with product across state borders.

What the April 23 DOJ Order Actually Did

Photo by Mark Stebnicki via Pexels.

The DOJ order signed by Blanche does two concrete things, and it's worth being precise about both because the difference between them is where most of the confusion online is coming from. First, it reclassifies FDA-approved marijuana drug products into Schedule III -- think products that have gone through an actual FDA approval process, similar to how Epidiolex was handled years earlier. Second, it reclassifies marijuana that's cultivated, processed, and sold under a qualifying state medical marijuana license. That second category is the one generating the buzz, because it's the first time federal law has carved out room for state-licensed medical cannabis operators specifically.

Crucially, the order says nothing about adult-use or recreational marijuana. That category remains Schedule I, and moving it across state lines remains a federal crime regardless of what any state's recreational law allows. What the order does create, for the medical and research categories, is a new legal right to transact and physically transport cannabis between facilities that hold DEA registration, even when those facilities sit in different states. It also opens the door for cannabis to be shipped and used specifically for medical research purposes, which researchers have been requesting for years given how difficult it's historically been to source study-grade cannabis.

This whole sequence fulfills the directive Trump gave then-Attorney General Pam Bondi back in December, when he instructed her to move on rescheduling "in the most expeditious manner," pointing specifically to a 2023 HHS study that had recommended moving marijuana to Schedule III. It took roughly four months from that directive to Blanche's signature, which by federal rulemaking standards counts as fast.

Why This Isn't Full Interstate Legalization

Photo by Pavel Danilyuk via Pexels.

Ask most cannabis attorneys and policy watchers about the April 23 order and you'll hear some version of the same caution: this is not the broad legalization of interstate commerce that a lot of headlines imply. It's a narrow medical and research carve-out, full stop. Vince Ning, CEO of the cannabis logistics platform Nabis, put it bluntly in comments following the order -- rescheduling doesn't automatically mean medical or adult-use products start flowing freely between states. There's a regulatory structure that has to get built first, and that structure isn't finished.

Part of what's still missing is the mechanical stuff that determines whether any of this is usable in practice. The DEA has set an end-of-June 2026 deadline for companies to apply for registration under the new interstate license structure, and the agency has said more detailed guidance is coming after that. Companies that want to participate in interstate medical cannabis transactions need to actually go through this registration process -- rescheduling alone doesn't grant blanket permission.

There's also a bigger question hanging over all of this. DEA Administrator Terry Cole confirmed that a follow-up hearing will begin June 29, 2026, to consider a broader question: whether to reschedule cannabis more comprehensively, beyond just the medical and research categories addressed in April. Cole described the overall effort as "bringing consistency and oversight to an area that has lacked both," language that signals incremental, careful movement rather than a single sweeping policy change. Until that hearing concludes and produces some kind of outcome, the April order is the ceiling, not the floor, of what's federally permitted.

Glass House's Shipment vs. the State Law Roadblock

Photo by Cannafornia via Pexels.

The clearest real-world test case so far comes from Glass House, the California cultivator that's become one of the largest cannabis growers in the state. Glass House says the DEA has approved its bulk exporter registration and that its first interstate shipment under the new framework has already taken place. Company president Graham Farrar summed up the moment simply: "Everything they said would happen is actually happening." It's a notable milestone -- an actual shipment, not just a policy announcement.

But dig into how that shipment became possible and you find the real bottleneck in this whole story, and it isn't federal. It's state law. California's cannabis regulator has confirmed that Glass House shared proposed statutory language that would let DEA-registered, state-licensed cannabis businesses ship product out of state or internationally. Proposed. As in, no such bill currently exists on the books in California, the state with arguably the most mature cannabis market in the country. Glass House's shipment appears to have moved through federal channels that are technically open, but the broader legal framework that would let other California licensees do the same thing routinely hasn't been enacted yet.

That distinction matters enormously for anyone else in the industry watching this unfold. A single company securing DEA approval for a bulk export registration and completing one shipment is not the same thing as an industry-wide green light. States still have to pass their own enabling legislation before their licensees can actually use this new federal pathway. Businesses in other states, watching California's headlines, should not assume they're free to start shipping product across state lines without a corresponding change in their own state's law. Confirm your state's specific statutory posture before acting on any of this.

A Second Deadline Looms: The Hemp Rule Change

Photo by RDNE Stock project via Pexels.

While marijuana rescheduling has dominated headlines, a separate and arguably more disruptive deadline is approaching for the hemp side of the industry, and it's getting far less attention than it deserves. Section 781 of the Continuing Appropriations and Extensions Act, 2026 (P.L. 119-37) takes effect November 12, 2026, and it fundamentally rewrites how hemp is defined under federal law.

The current legal definition of hemp, established by the 2018 Farm Bill, is based on delta-9 THC content measured at a specific threshold. That definition left a loophole that the hemp-derived products industry has built an enormous business around, particularly involving THCA, which converts to intoxicating THC when heated but technically doesn't count under the old delta-9-only measurement. Section 781 closes that loophole by moving to a total-THC standard that explicitly includes THCA in the calculation. New hemp products under this rule will be capped at 0.4 milligrams of total THC per container -- an extremely low threshold compared to what's on shelves today.

The practical impact of this change is hard to overstate. Industry estimates suggest this new standard could affect roughly 95% of hemp products currently on the market, from gummies to beverages to flower marketed as hemp-derived. For a huge swath of retailers, particularly those outside states with adult-use marijuana programs who've relied on hemp-derived THC products to serve customers, this is a far bigger and more immediate disruption than anything happening with marijuana rescheduling. Businesses selling hemp-derived THC products should be reviewing their formulations against this new total-THC standard now, not waiting until the fall to figure out whether their entire product line becomes non-compliant overnight.

What Businesses Should Actually Do Right Now

Photo by Sadi Hockmuller via Pexels.

If you're running a cannabis or hemp business right now, the useful move isn't to celebrate rescheduling headlines -- it's to get specific about what actually applies to you. Start by checking whether your state has passed, or is even drafting, legislation that aligns with the DEA's new medical interstate framework. As of now, most states, including California, don't have one, so don't assume your state license lets you ship anywhere just because the federal door has cracked open.

Keep an eye on the June 29, 2026 DEA hearing as well. That's the session where broader rescheduling of all cannabis categories, not just the medical and research carve-outs from April, gets discussed. Whatever comes out of that hearing will shape what's possible over the next several years far more than the April order did on its own.

If your business touches hemp in any way, put the November 12, 2026 total-THC deadline on your calendar and start auditing product formulations against it immediately. Waiting until autumn to discover your flagship product doesn't comply is not a position you want to be in, especially with retail inventory and supply contracts to manage.

Above all, treat every piece of rescheduling news with a healthy dose of skepticism about what it actually authorizes. Federal reclassification is one layer of a multi-layer system, and state law still governs what you can legally grow, sell, ship, or purchase where you are. Given how fast this landscape is shifting, verify current law in your specific state, ideally with a cannabis attorney, before making any business or purchasing decisions based on federal headlines alone.

Strip away the headlines and what you're left with is this: a federal pathway for interstate medical cannabis commerce now technically exists on paper, complete with a DEA registration process and at least one documented shipment to prove it's not purely theoretical. But "exists on paper" and "usable by most businesses" are very different things, and right now almost no state has built the on-ramp that would let its licensees actually drive onto that federal highway.

If you want a real signal for when interstate shipments become routine rather than a single company's pilot run, watch your state legislature, not the DEA's press releases. California's own regulator has already said as much -- the proposed statutory changes exist only as a proposal. Every other state is presumably somewhere further back in that same process, if they've started it at all.

And for a lot of operators, especially those in the hemp space, the marijuana rescheduling story might turn out to be the less urgent one. The November 12, 2026 total-THC rule is set, dated, and poised to reshape product formulations across an industry that's grown accustomed to the old delta-9 loophole. That's the deadline worth losing sleep over this year.